阿司匹林治疗血栓性脑梗死的临床疗效及安全性分析

Clinical efficacy and safety analysis of aspirin in the treatment of thrombotic cerebral infarction

目的分析阿司匹林治疗血栓性脑梗死的临床疗效及安全性。方法选取2019—2020年重庆市九龙坡区人民医院收治的急诊血栓性脑梗死患者96例,根据治疗方法不同分为对照组(48例)和观察组(48例)。对照组予以常规治疗,观察组在常规治疗基础上加用阿司匹林口服治疗,2组患者均连续治疗14 d。比较2组临床疗效,治疗前后神经功能缺损程度[采用美国国立卫生研究院卒中量表(NIHSS)评分评估]、日常生活活动能力(采用Barthel指数评估)、凝血功能指标[凝血酶原时间(PT)、部分活化凝血活酶时间(APTT)、纤维蛋白原(FIB)及D-二聚体],并观察2组治疗期间不良反应发生情况。结果观察组治疗总有效率为97.9%(47/48),高于对照组的83.3%(40/48)(P<0.05)。观察组患者治疗后NIHSS评分低于对照组,Barthel指数高于对照组(P<0.05)。观察组患者治疗后PT、APTT短于对照组,FIB、D-二聚体低于对照组(P<0.05)。观察组患者不良反应发生率为4.2%(2/48),与对照组患者的10.5%(5/48)相比,差异无统计学意义(P>0.05)。结论阿司匹林用于治疗血栓性脑梗死可取得良好的临床疗效,可降低患者神经功能缺损程度,提高患者日常生活活动能力,改善患者凝血功能,且未增加药物相关不良反应。

Objective To analyze the clinical efficacy and safety analysis of aspirin in the treatment of thrombotic cerebral infarction.Methods A total of 96 patients with emergency thrombotic cerebral infarction treated in People’s Hospital of Jiulongpo District from 2019 to 2020 were selected and divided into control group(48 cases)and observation group(48 cases)according to different treatment methods.The control group was treated with routine treatment,and the observation group was treated with aspirin on the basis of routine treatment.Both groups were treated for 14 days.The clinical effects,the degree of neurological deficit[assessed by the National Institutes of Health Stroke Scale(NIHSS)],activities of daily living(assessed by Barthel Index),coagulation function indexes[prothrombin time(PT),partially activated thromboplastin time(APTT),fibrinogen(FIB)and D-dimer]before and after treatment were compared between the two groups;and the adverse reactions of the two groups during treatment were observed.Results The total effective rate of the observation group was higher than that of the control group(97.9%vs 83.3%)(P<0.05).After treatment,NIHSS score of the observation group was lower than that of the control group,and Barthel index was higher than that of the control group(P<0.05).After treatment,PT and APTT of the observation group were shorter than those in the control group,and FIB and D-dimer were lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was 4.2%(2/48),and there was no significant difference compared with 10.5%(5/48)in the control group(P>0.05).Conclusion Aspirin in the treatment of thrombotic cerebral infarction can achieve good clinical efficacy,reduce the degree of neurological deficit,improve the ability of daily living,improve the coagulation function,and do not increase drug-related adverse reactions.